Patients are at the Center of Everything We Do
American Society of Clinical Oncology Annual Meeting 2020
A Letter from Our CEO
It’s hard to believe that this time a year ago, we were together in Chicago. A sea of physicians, researchers, patient advocates and other medical professionals gathered on behalf of patients to advance cancer research and clinical programs on behalf of patients.
Today, we all find ourselves in a vastly different world, but this new world is particularly challenging for cancer patients. In addition to the difficulties and anxiety associated with a cancer diagnosis, they are confronted with an unprecedented global healthcare crisis that threatens many aspects of their lives. The COVID-19 pandemic is a danger to the immunocompromised; it has also separated families and, in many places, slowed cancer research as laboratories have their activities put on hold and as clinical trial sites have needed to shift resource deployment. Perhaps worse, many patients have been forced into isolation.
For those of us who are not on the frontlines of this pandemic, we maintain a steady focus where we can have the most impact: driving medical innovation forward. At Agios, we are proud to be part of this dedicated community and of the great work ASCO has done to bring us together safely and creatively to continue to advance our collective mission through a virtual conference.
We have created a space for you here to read about the important progress we’re making at Agios as we continue to forge novel paths to treating cancer and rare genetic diseases by targeting cellular metabolism.
We look forward to sharing with you updated data from our IDH program in low-grade glioma. This is a disease for which long-term prognosis is currently poor, and too often it is discovered when patients are in the prime of their lives, starting families and building their careers. At this year’s conference, we will be presenting encouraging updated data from the Phase 1 study of our investigational therapy vorasidenib specifically in patients with non-enhancing glioma. These data further support our ongoing global Phase 3 INDIGO study, which is intended to evaluate whether vorasidenib could provide a targeted therapeutic alternative to “watch and wait” for these patients to help control their disease and potentially delay the need for chemotherapy and/or radiation.
We continue to build on our leadership in hematologic malignancies by generating new combination data for our mutant-IDH1 inhibitor ivosidenib. I’d encourage you to review the promising data presented by our colleagues at the MD Anderson Cancer Center and the University of Oxford from their investigator-sponsored trial (IST) exploring ivosidenib in combination with venetoclax, with or without azacitidine, in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). In addition, we look forward to sharing an update on our ongoing Phase 3 AGILE trial evaluating ivosidenib in combination with azacitidine in patients with previously untreated AML.
As we push forward for patients, I invite you to follow us on Twitter and LinkedIn to continue the conversation. Now more than ever, it’s important to stay in touch with our distant colleagues and friends.
Jackie Fouse, Ph.D.
Chief Executive Officer